In 2011, the Food and Drug Administration (FDA) approved vemurafenib as the first BRAF targeted therapy for unresectable or metastatic BRAF V600E-mutated melanoma based on an overall survival rate of 84%and a 63% decrease in the risk of mortality from the BRIM 3 trial (20). This evidence concerns the gene BRAF and melanoma.